An explainable machine learning ensemble model to predict the risk of ovarian cancer in BRCA-mutated patients undergoing risk-reducing salpingo-oophorectomy
نویسندگان
چکیده
Introduction It has been estimated that 19,880 new cases of ovarian cancer had diagnosed in 2022. Most epithelial are sporadic, while 15%–25% cases, there is evidence a familial or inherited component. Approximately 20%–25% high-grade serous carcinoma caused by germline mutations the BRCA1 and BRCA2 genes. However, owing to lack effective early detection methods, women with BRCA recommended undergo bilateral risk-reducing salpingo-oophorectomy (RRSO) after childbearing. Determining right timing for this procedure difficult decision. crucial find clinical signature identify high-risk BRCA-mutated patients determine appropriate performing RRSO. Methods In work, data referred cohort 184 patients, whom 7.6% were affected adnexal tumors including invasive carcinomas intraepithelial lesions RSSO analyzed. Thus, we proposed an explainable machine learning (ML) ensemble approach using commonly collected practice at high risk consequentially establish correct Results The model was able handle imbalanced achieving accuracy value 83.2%, specificity 85.3%, sensitivity 57.1%, G-mean 69.8%, AUC 71.1%. Discussion agreement promising results achieved, application suitable ML techniques could play key role definition patient-centric consequently personalize management these patients. As far as know, first work addressing task from perspective.
منابع مشابه
Risk-reducing salpingo-oophorectomy for BRCA mutation carriers.
It has been twenty years since the region of the BRCA1mutationwas identified on chromosome 17q. There are now over 3000 risk reducing salpingo-oophorectomy (RRSO) cases reported and an estimated 150 cases describing unsuspected cancers of the ovaries and tubes or in situ lesions. Connor et al. in their current study add to the literature on RRSO outcomes [1]. They report on 345 cases of RRSO in...
متن کاملRisk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers
BACKGROUND Women with BRCA1 and BRCA2 mutation carriers are at substantially elevated risk of developing ovarian cancer. The aim of the meta-analysis is to clarify the role of risk-reducing salpingo-oophorectomy (RRSO) to reduce ovarian cancer risk and mortality in women with BRCA 1 and BRCA 2 mutation carriers. METHODS Pubmed, Medline and Scopus were searched to select English-language artic...
متن کاملOccult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
Women who carry deleterious mutations of the BRCA1 or BRCA2 gene are the largest identifiable population at high risk for ovarian cancer and account for 10% of all cases. The lifetime risk of ovarian cancer in women with BRCA1 mutations ranges from 20 to 65% and the lifetime risk in BRCA2 mutation carriers is approximately 20% [1,2]. Women with BRCA1/2 mutations are also known to be at risk for...
متن کاملDefining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women.
OBJECTIVE To define risk thresholds for cost-effectiveness of risk-reducing salpingo-oophorectomy (RRSO) for ovarian cancer (OC) prevention in low/intermediate risk postmenopausal women. METHODS A decision-analytic model compares lifetime costs-&-effects of offering 'RRSO' with 'no RRSO' to postmenopausal women ≥50years for different lifetime OC-risk thresholds: 2%, 4%, 5%, 6%, 8% and 10%. We...
متن کاملRole of genetic testing for screening and prevention for ovarian cancer: comment on "Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing".
BACKGROUND For women at potentially increased risk for ovarian cancer, data regarding screening and risk reduction are limited. Previous studies have reported on the behaviors of BRCA mutation carriers, but less is known about the behaviors of non- BRCA carriers. We surveyed a large cohort of women after BRCA testing to identify the prevalence and posttest predictors of risk-reducing and screen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Oncology
سال: 2023
ISSN: ['2234-943X']
DOI: https://doi.org/10.3389/fonc.2023.1181792